148 related articles for article (PubMed ID: 38742199)
21. Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
Abbara A; Clarke SA; Brewster R; Simonnard A; Eng PC; Phylactou M; Papadopoulou D; Izzi-Engbeaya C; Sam AH; Wernig F; Jonauskyte E; Comninos AN; Meeran K; Kelsey TW; Dhillo WS
Front Endocrinol (Lausanne); 2020; 11():286. PubMed ID: 32477269
[No Abstract] [Full Text] [Related]
22. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
23. Changes in thyroid function in patients with liver failure and their clinical significance: A clinical study of non-thyroidal illness syndrome in patients with liver failure.
Feng HL; Li Q; Cao WK; Yang JM
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):561-566. PubMed ID: 32535064
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-21 is associated with disease activity in patients with Graves' disease.
Zhang J; Zeng H; Ren M; Yan H; Xu M; Feng Z; Liang W; Yang C; Cheng H; Ding H; Yan L
Endocrine; 2014 Aug; 46(3):539-48. PubMed ID: 24287789
[TBL] [Abstract][Full Text] [Related]
25. Thyroid function, body mass index, and metabolic risk markers in euthyroid adults: a cohort study.
Xu R; Huang F; Zhang S; Lv Y; Liu Q
BMC Endocr Disord; 2019 Jun; 19(1):58. PubMed ID: 31174521
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.
Katahira M; Tsunekawa T; Mizoguchi A; Yamaguchi M; Tsuru K; Takashima H; Terada R
Hormones (Athens); 2023 Jun; 22(2):253-261. PubMed ID: 36811756
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic factors in the relapse of Graves disease].
Miao J; Zhao YJ; Wang S; Jiang XH; Zhao ZF; Gu LQ; Gu XJ; Ning G
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):185-8. PubMed ID: 18785498
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
29. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
[TBL] [Abstract][Full Text] [Related]
30. RELATIONSHIP BETWEEN THE EFFECTIVENESS OF INORGANIC IODINE AND THE SEVERITY OF GRAVES THYROTOXICOSIS: A RETROSPECTIVE STUDY.
Honda A; Uchida T; Komiya K; Goto H; Takeno K; Sato J; Suzuki R; Himuro M; Watada H
Endocr Pract; 2017 Dec; 23(12):1408-1413. PubMed ID: 29144795
[TBL] [Abstract][Full Text] [Related]
31. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
[TBL] [Abstract][Full Text] [Related]
32. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
33. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.
Xu B; Wu D; Ying H; Zhang Y
Turk J Med Sci; 2019 Jun; 49(3):715-722. PubMed ID: 31023005
[TBL] [Abstract][Full Text] [Related]
34. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
Tajiri J; Noguchi S; Morita M; Tamaru M; Murakami N; Kato R
Endocrinol Jpn; 1991 Dec; 38(6):683-7. PubMed ID: 1726635
[TBL] [Abstract][Full Text] [Related]
35. Thyroid Parameters and Kidney Disorder in Type 2 Diabetes: Results from the METAL Study.
Chen Y; Zhang W; Wang N; Wang Y; Wang C; Wan H; Lu Y
J Diabetes Res; 2020; 2020():4798947. PubMed ID: 32337292
[TBL] [Abstract][Full Text] [Related]
36. Rapid preoperative blockage of thyroid hormone production / secretion in patients with Graves' disease.
Fischli S; Lucchini B; Müller W; Slahor L; Henzen C
Swiss Med Wkly; 2016; 146():w14243. PubMed ID: 26765838
[TBL] [Abstract][Full Text] [Related]
37. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave's disease.
Peng Y; Qi Y; Huang F; Chen X; Zhou Y; Ye L; Wang W; Ning G; Wang S
Oncotarget; 2016 Nov; 7(48):78680-78687. PubMed ID: 27637079
[TBL] [Abstract][Full Text] [Related]
38. Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
Nisman B; Allweis TM; Carmon E; Kadouri L; Maly B; Maimon O; Meierovich A; Peretz T
Anticancer Res; 2020 Nov; 40(11):6417-6428. PubMed ID: 33109580
[TBL] [Abstract][Full Text] [Related]
39. Predictive Value of Free Triiodothyronine to Free Thyroxine Ratio in Euthyroid Patients With Myocardial Infarction With Nonobstructive Coronary Arteries.
Gao S; Ma W; Huang S; Lin X; Yu M
Front Endocrinol (Lausanne); 2021; 12():708216. PubMed ID: 34394005
[TBL] [Abstract][Full Text] [Related]
40. The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study.
Sasson M; Kay-Rivest E; Shoukrun R; Florea A; Hier M; Forest VI; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):28. PubMed ID: 28376913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
